WHOOP, Field Trip partner to study impact of psychedelic therapies
Category: #health  | By Nikita Chaurasia  | Date: 2020-11-21 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

WHOOP, Field Trip partner to study impact of psychedelic therapies

WHOOP Inc., a prominent provider of health tracking and monitoring services, has reportedly announced a partnership with Field Trip Health Ltd., leader in development and delivery of psychedelic therapies. According to reliable sources, Field Trip will use WHOOP’s Strap 3.0 in order to determine biometric effects of its psychedelic therapies on mental and physiology health.

Field Trip reportedly intends to perform an observational study to understand if its ketamine-assisted therapies, which have been proved to be beneficial in treating mental health conditions including PTSD, anxiety, and depression, could improve physical health as well.

It is to be noted that, Field Trip has acquired WHOOP products and has gained access to additional data insights through a research collaboration and enterprise program. The firm is also planning to open Field Trip Health centers across Europe and North America for delivering their psychedelic therapies.

Dr. Ryan Yermus, Chief Clinical Officer at Field Trip, mentioned in a comment that clinical outcomes from their first three centers in Los Angeles, New York, and Toronto, have been overwhelmingly positive, with a substantial decrease in depressive symptoms, trauma-related symptoms, and anxiety.

If reports are to be believed, the research will initially be conducted on military veterans seeking ketamine-assisted therapies via Basecamp program of Field Trip and then expand to the generic public.

Some studies have already proved that physiological metrics such as slow wave sleep patterns and HRV will be improved via psychedelic therapies of Field Trip, sources confirmed. The potential collaboration between the two companies is to better understand the connection between physiology and mental wellbeing.

As per credible sources, WHOOP was recently valued at USD 1.2 billion after receiving over USD 100 million in a Series E funding round. At present, the company's bands are being used in a COVID-19 vaccine trials and have also been used on the LPGA tour to track the health of sports players.

Source Credits- https://www.globenewswire.com/news-release/2020/11/19/2130016/0/en/Field-Trip-Health-Ltd-and-WHOOP-announce-partnership-to-measure-effect-of-psychedelic-therapies-on-physiology-and-mental-health.html

 

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

EasyJet sees a rise in bookings as customers plan their next vacations

EasyJet sees a rise in bookings as customers plan their next vacations

By Nikita Chaurasia

British multinational low-cost airline group, EasyJet, has reported a record surge in bookings for the month of January as people prioritized their travel plans for the coming year. The news comes as airlines world over start to show signs that they&...

Dr. Reddy’s becomes India’s second biggest drugmaker by sales

Dr. Reddy’s becomes India’s second biggest drugmaker by sales

By Nikita Chaurasia

Dr. Reddy's Laboratories Ltd. and Cipla Ltd. surpassed Aurobindo Pharma to rank as the 2nd and 3rd largest drug manufacturers in India by sales in the three months that ended on September 30. This was the first change in the pecking order of the ...

UK’s business confidence drops to its lowest point since 2009

UK’s business confidence drops to its lowest point since 2009

By Nikita Chaurasia

According to recent data, business confidence in the UK dropped to 18% in October, which was its lowest level in at least 13 years. In contrast, however, net balances of confidence stood at 28% in June and 56% in February, according to Accenture and ...